Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease
BackgroundsNumerous lines of evidence support the intricate interplay between Parkinson’s disease (PD) and the PINK1-dependent mitophagy process. This study aimed to evaluate differences in plasma PINK1 levels among idiopathic PD, PD syndromes (PDs), and healthy controls.MethodsA total of 354 partic...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Aging Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnagi.2024.1369014/full |
| _version_ | 1797198735973810176 |
|---|---|
| author | Xianchai Hong Yi Zheng Jialong Hou Tao Jiang Yao Lu Yao Lu Wenwen Wang Shuoting Zhou Qianqian Ye Chenglong Xie Chenglong Xie Chenglong Xie Chenglong Xie Jia Li |
| author_facet | Xianchai Hong Yi Zheng Jialong Hou Tao Jiang Yao Lu Yao Lu Wenwen Wang Shuoting Zhou Qianqian Ye Chenglong Xie Chenglong Xie Chenglong Xie Chenglong Xie Jia Li |
| author_sort | Xianchai Hong |
| collection | DOAJ |
| description | BackgroundsNumerous lines of evidence support the intricate interplay between Parkinson’s disease (PD) and the PINK1-dependent mitophagy process. This study aimed to evaluate differences in plasma PINK1 levels among idiopathic PD, PD syndromes (PDs), and healthy controls.MethodsA total of 354 participants were included, consisting of 197 PD patients, 50 PDs patients, and 107 healthy controls were divided into two cohorts, namely the modeling cohort (cohort 1) and the validated cohort (cohort 2). An enzyme-linked immunosorbent assay (ELISA)-based analysis was performed on PINK1 and α-synuclein oligomer (Asy-no). The utilization of the area under the curve (AUC) within the receiver-operating characteristic (ROC) curves served as a robust and comprehensive approach to evaluate and quantify the predictive efficacy of plasma biomarkers alone, as well as combined models, in distinguishing PD patients from controls.ResultsPINK1 and Asy-no were elevated in the plasma of PD and PDs patients compared to healthy controls. The AUCs of PINK1 (0.771) and Asy-no (0.787) were supposed to be potentially eligible plasma biomarkers differentiating PD from controls but could not differentiate PD from PDs. Notably, the PINK + Asy-no + Clinical RBD model showed the highest performance in the modeling cohort and was comparable with the PINK1 + Clinical RBD in the validation cohort. Moreover, there is no significant correlation between PINK1 and UPDRS, MMSE, HAMD, HAMA, RBDQ-HK, and ADL scores.ConclusionThese findings suggest that elevated PINK1 in plasma holds the potential to serve as a non-invasive tool for distinguishing PD patients from controls. Moreover, the outcomes of our investigation lend support to the plausibility of implementing a feasible blood test in future clinical translation. |
| first_indexed | 2024-04-24T07:04:35Z |
| format | Article |
| id | doaj.art-b1c948544d85445190d339b298adea58 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-04-24T07:04:35Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-b1c948544d85445190d339b298adea582024-04-22T04:33:19ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652024-04-011610.3389/fnagi.2024.13690141369014Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s diseaseXianchai Hong0Yi Zheng1Jialong Hou2Tao Jiang3Yao Lu4Yao Lu5Wenwen Wang6Shuoting Zhou7Qianqian Ye8Chenglong Xie9Chenglong Xie10Chenglong Xie11Chenglong Xie12Jia Li13Department of Neurology Nursing Unit 362 Ward, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, Yuhuan City People's Hospital, Taizhou, ChinaThe Center of Traditional Chinese Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaKey Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou City, ChinaInstitute of Aging, Wenzhou Medical University, Wenzhou, Zhejiang, ChinaOujiang Laboratory, Wenzhou, Zhejiang, ChinaDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, ChinaBackgroundsNumerous lines of evidence support the intricate interplay between Parkinson’s disease (PD) and the PINK1-dependent mitophagy process. This study aimed to evaluate differences in plasma PINK1 levels among idiopathic PD, PD syndromes (PDs), and healthy controls.MethodsA total of 354 participants were included, consisting of 197 PD patients, 50 PDs patients, and 107 healthy controls were divided into two cohorts, namely the modeling cohort (cohort 1) and the validated cohort (cohort 2). An enzyme-linked immunosorbent assay (ELISA)-based analysis was performed on PINK1 and α-synuclein oligomer (Asy-no). The utilization of the area under the curve (AUC) within the receiver-operating characteristic (ROC) curves served as a robust and comprehensive approach to evaluate and quantify the predictive efficacy of plasma biomarkers alone, as well as combined models, in distinguishing PD patients from controls.ResultsPINK1 and Asy-no were elevated in the plasma of PD and PDs patients compared to healthy controls. The AUCs of PINK1 (0.771) and Asy-no (0.787) were supposed to be potentially eligible plasma biomarkers differentiating PD from controls but could not differentiate PD from PDs. Notably, the PINK + Asy-no + Clinical RBD model showed the highest performance in the modeling cohort and was comparable with the PINK1 + Clinical RBD in the validation cohort. Moreover, there is no significant correlation between PINK1 and UPDRS, MMSE, HAMD, HAMA, RBDQ-HK, and ADL scores.ConclusionThese findings suggest that elevated PINK1 in plasma holds the potential to serve as a non-invasive tool for distinguishing PD patients from controls. Moreover, the outcomes of our investigation lend support to the plausibility of implementing a feasible blood test in future clinical translation.https://www.frontiersin.org/articles/10.3389/fnagi.2024.1369014/fullPINK1α-synuclein oligomerbiomarkersmitophagyParkinson’s disease |
| spellingShingle | Xianchai Hong Yi Zheng Jialong Hou Tao Jiang Yao Lu Yao Lu Wenwen Wang Shuoting Zhou Qianqian Ye Chenglong Xie Chenglong Xie Chenglong Xie Chenglong Xie Jia Li Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease Frontiers in Aging Neuroscience PINK1 α-synuclein oligomer biomarkers mitophagy Parkinson’s disease |
| title | Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease |
| title_full | Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease |
| title_fullStr | Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease |
| title_full_unstemmed | Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease |
| title_short | Detection of elevated levels of PINK1 in plasma from patients with idiopathic Parkinson’s disease |
| title_sort | detection of elevated levels of pink1 in plasma from patients with idiopathic parkinson s disease |
| topic | PINK1 α-synuclein oligomer biomarkers mitophagy Parkinson’s disease |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2024.1369014/full |
| work_keys_str_mv | AT xianchaihong detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT yizheng detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT jialonghou detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT taojiang detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT yaolu detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT yaolu detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT wenwenwang detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT shuotingzhou detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT qianqianye detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT chenglongxie detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT chenglongxie detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT chenglongxie detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT chenglongxie detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease AT jiali detectionofelevatedlevelsofpink1inplasmafrompatientswithidiopathicparkinsonsdisease |